Effect of CGS 20267 on ovarian aromatase and gonadotropin levels in the rat
- PMID: 9541188
- DOI: 10.1023/a:1005937900788
Effect of CGS 20267 on ovarian aromatase and gonadotropin levels in the rat
Abstract
Aromatase catalyzes the rate limiting step that converts androgens to estrogens. Postmenopausal women with hormone dependent breast cancer respond to first generation aromatase inhibitors such as aminoglutethimide with a marked suppression of circulating estradiol levels. In contrast, premenopausal women appear to be resistant to first generation aromatase inhibitors. The inability to block ovarian aromatase results from the low affinity of first generation inhibitors for the active site of the enzyme. Under these circumstances, the high substrate levels in the premenopausal ovary compete effectively with these inhibitors and do not allow binding of inhibitor to the active site of the enzyme. Second and third generation aromatase inhibitors with higher affinity for aromatase have now been developed and potentially could block ovarian aromatase. To test this possibility, we administered CGS 20267 (letrozole), a highly potent aromatase inhibitor, to cycling female rats. A dose dependent inhibition of uterine weight occurred with maximum effects produced by the 5 mg/kg/day dosage. During a period of 4 weeks, uterine weight was reduced to levels induced by ovariectomy. Ovarian tissue estradiol levels were inhibited by approximately 80%. As a reflection of inhibition of ovarian aromatase activity, the levels of androstenedione in the ovary increased by an order of magnitude. Both LH and FSH plasma levels increased but not to those observed after ovariectomy. The rise in gonadotropin levels induced a statistically significant but relatively small increase in ovarian weights. These results demonstrate the ability to persistently block ovarian aromatase activity in cycling rats with a potent aromatase inhibitor. This study provides a rationale for clinical trials of potent aromatase inhibitors in pre-menopausal women with breast cancer.
Similar articles
-
In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.Clin Cancer Res. 1995 Dec;1(12):1511-5. Clin Cancer Res. 1995. PMID: 9815951 Clinical Trial.
-
The potent and selective inhibition of estrogen production by non-steroidal aromatase inhibitor, YM511.J Steroid Biochem Mol Biol. 1995 Sep;54(5-6):265-71. doi: 10.1016/0960-0760(95)00136-n. J Steroid Biochem Mol Biol. 1995. PMID: 7577709
-
The role of estrogen in the feedback regulation of follicle-stimulating hormone secretion in the female rat.J Steroid Biochem Mol Biol. 1993 Dec;47(1-6):161-6. doi: 10.1016/0960-0760(93)90070-d. J Steroid Biochem Mol Biol. 1993. PMID: 8274431
-
Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor.J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):1021-7. doi: 10.1016/0960-0760(90)90460-3. J Steroid Biochem Mol Biol. 1990. PMID: 2149502 Review.
-
[Aromatase inhibitors: pharmacological aspects].Bull Cancer. 2000 Dec;87 Spec No:23-29. Bull Cancer. 2000. PMID: 11250605 Review. French.
Cited by 8 articles
-
Chemoprevention of LA7-Induced Mammary Tumor Growth by SM6Met, a Well-Characterized Cyclopia Extract.Front Pharmacol. 2018 Jun 20;9:650. doi: 10.3389/fphar.2018.00650. eCollection 2018. Front Pharmacol. 2018. PMID: 29973879 Free PMC article.
-
Assessment of the luteal phase in stimulated and substituted cycles.Facts Views Vis Obgyn. 2009;1(1):30-46. Facts Views Vis Obgyn. 2009. PMID: 25478069 Free PMC article. No abstract available.
-
The impact of letrozole versus clomiphene citrate on uterine blood flow in patients with unexplained infertility.J Family Reprod Health. 2014 Mar;8(1):1-5. J Family Reprod Health. 2014. PMID: 24971126 Free PMC article.
-
Luteinizing hormone-releasing hormone agonist plus an aromatase inhibitor as second-line endocrine therapy in premenopausal females with hormone receptor-positive metastatic breast cancer.Surg Today. 2014 Sep;44(9):1678-84. doi: 10.1007/s00595-013-0765-4. Epub 2013 Nov 12. Surg Today. 2014. PMID: 24218007
-
A computational model to predict rat ovarian steroid secretion from in vitro experiments with endocrine disruptors.PLoS One. 2013;8(1):e53891. doi: 10.1371/journal.pone.0053891. Epub 2013 Jan 11. PLoS One. 2013. PMID: 23326527 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
-
Full Text Sources
-
Other Literature Sources